A detailed history of First Republic Investment Management, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 2,158 shares of BGNE stock, worth $386,411. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,158
Previous 2,598 16.94%
Holding current value
$386,411
Previous $463,000 16.2%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$179.87 - $225.13 $79,142 - $99,057
-440 Reduced 16.94%
2,158 $388,000
Q2 2023

Jul 28, 2023

SELL
$178.3 - $266.78 $504,767 - $755,254
-2,831 Reduced 52.15%
2,598 $463,000
Q1 2023

May 11, 2023

BUY
$215.53 - $274.5 $20,475 - $26,077
95 Added 1.78%
5,429 $1.17 Million
Q4 2022

Feb 13, 2023

SELL
$125.51 - $229.3 $144,587 - $264,153
-1,152 Reduced 17.76%
5,334 $1.17 Million
Q3 2022

Nov 03, 2022

SELL
$131.8 - $202.24 $43,230 - $66,334
-328 Reduced 4.81%
6,486 $874,000
Q2 2022

Aug 16, 2022

SELL
$121.11 - $216.05 $8,235 - $14,691
-68 Reduced 0.99%
6,814 $1.1 Million
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $307,398 - $565,536
2,098 Added 43.85%
6,882 $1.3 Million
Q4 2021

Feb 09, 2022

BUY
$248.56 - $389.34 $32,312 - $50,614
130 Added 2.79%
4,784 $1.3 Million
Q3 2021

Nov 12, 2021

BUY
$249.6 - $403.14 $70,137 - $113,282
281 Added 6.43%
4,654 $1.69 Million
Q2 2021

Aug 16, 2021

BUY
$292.75 - $367.01 $210,780 - $264,247
720 Added 19.71%
4,373 $1.5 Million
Q1 2021

May 14, 2021

SELL
$260.64 - $382.12 $1,042 - $1,528
-4 Reduced 0.11%
3,653 $1.27 Million
Q4 2020

Feb 16, 2021

BUY
$221.31 - $316.61 $175,277 - $250,755
792 Added 27.64%
3,657 $945,000
Q3 2020

Nov 12, 2020

BUY
$189.18 - $286.44 $542,000 - $820,650
2,865 New
2,865 $821,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.